Antithrombin alfa

Drug Profile

Antithrombin alfa

Alternative Names: Antithrombin III recombinant human; Antithrombin III transgenic; ATryn; Recombinant human antithrombin III; rhATIII; Transgenic antithrombin III

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GTC Biotherapeutics
  • Developer GTC Biotherapeutics; Knight Therapeutics; LEO Pharma; rEVO Biologics
  • Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Antithrombin III deficiency; Blood coagulation disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes - Antithrombin III deficiency; Blood coagulation disorders

Highest Development Phases

  • Marketed Antithrombin III deficiency
  • Phase III Blood coagulation disorders; Preeclampsia
  • Discontinued Acute lung injury; Burns; Disseminated intravascular coagulation; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Coagulation-disorders(In neonates) in USA (Parenteral)
  • 01 Nov 2016 rEVO Biologics completes a phase III trial in Preeclampsia in USA (IV) (NCT02059135)
  • 25 Apr 2016 Knight Therapeutics receives Notice of Deficiency from the Health Canada for antithrombin alfa in Antithrombin III deficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top